Single-cell transcriptomics market seen reaching $1.92B by 2030

The single-cell analysis transcriptomics market is projected to grow from $1.08 billion in 2025 to $1.22 billion in 2026, with long-term demand driven by personalized medicine, clinical diagnostics and new sequencing tools. The Business Research Company says the market could reach $1.92 billion by 2030, with North America leading now and Asia-Pacific expected to grow fastest.

Why it matters: - Single-cell transcriptomics helps researchers see gene activity at the level of individual cells, which can uncover rare cell types and disease signals that bulk tissue analysis can miss. - The market’s growth reflects rising demand for more precise tools in personalized medicine, drug discovery and clinical diagnostics. - The Business Research Company estimates the market will expand to $1.92 billion by 2030.

What happened: - The Business Research Company released a market study on the single-cell analysis transcriptomics market on Aug. 26, 2026. - The market is projected to rise from $1.08 billion in 2025 to $1.22 billion in 2026. - The forecast implies 12.3% growth in 2026 and 12.2% average annual growth through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Single-cell transcriptomics measures gene expression in individual cells. - The method helps identify cellular diversity inside complex tissues. - The technology supports mapping developmental pathways and understanding disease mechanisms. - Early market growth was constrained by high sequencing equipment costs. - Limited access to microfluidics technologies also slowed adoption. - Traditional reliance on bulk tissue analysis held back earlier use cases. - Increased academic research funding helped accelerate the market. - Greater awareness of cellular heterogeneity also supported adoption. - Future growth is tied to improvements in single-cell sequencing platforms. - Cloud-based bioinformatics solutions are becoming an important part of the market. - Pharmaceutical and biotechnology investment is adding momentum. - Hospitals and diagnostic centers are expanding use of the technology. - Major trends include broader use of single-cell RNA sequencing. - Additional trends include more microfluidics platforms, stronger clinical diagnostics use, drug discovery advances and better data analysis tools. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - A free sample report is available here. - The full report is available here.

Between the lines: - The forecast suggests single-cell transcriptomics is moving from a research-heavy niche toward broader commercial and clinical use. - Personalized medicine is a key demand driver because it relies on more detailed patient-level biological data. - The FDA approval of 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022, illustrates the broader push toward individualized care.

What's next: - Market growth is likely to depend on continued progress in sequencing performance, data analysis and cloud-based workflows. - Wider adoption in hospitals and diagnostic labs could expand the market beyond academic research. - Asia-Pacific could gain share if investment and infrastructure growth continue at the current pace. - The Business Research Company has also highlighted updated market-report tools, including forecasting dashboards and hotspot infographics, for its 2026 research releases.